Urogen Pharma LTD Form 4 insider transactions

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has sold 10,000 ordinary shares for approximately $400,000 as part of a pre-arranged trading plan.

UroGen Pharma Ltd. reports a significant stock transaction by Chief Medical Officer Mark Schoenberg, who sold 10,000 ordinary shares valued at approximately $350,100 under a pre-arranged trading plan.

UroGen Pharma Ltd. director Daniel George Wildman acquired 10,000 stock options and 8,000 Restricted Stock Units, indicating a significant equity grant.

UroGen Pharma director James A. Robinson Jr. reported the acquisition of stock options and restricted stock units, indicating a vested interest in the company's future.

UroGen Pharma Ltd. director Stuart Holden was granted 20,000 stock options with an exercise price of $34.99, vesting over one year.

Cynthia M. Butitta, a Director at UroGen Pharma Ltd., acquired 10,000 stock options and 8,000 Restricted Stock Units (RSUs) on June 22, 2026.

Director Leana Wen acquired 10,000 stock options and 8,000 restricted stock units in UroGen Pharma Ltd. on June 22, 2026.

Arie Belldegrun, a Director at UroGen Pharma Ltd., has acquired stock options for 20,000 ordinary shares.

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., reported transactions involving ordinary shares and restricted stock units.

UroGen Pharma Director James A. Robinson Jr. acquired 2,000 ordinary shares through restricted stock units.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 ordinary shares for $300,000 under a pre-arranged trading plan.

UroGen Pharma Ltd. Director James A. Robinson Jr. converted 2,000 restricted stock units into ordinary shares, increasing his direct beneficial ownership to 4,000 shares.

UroGen Pharma Ltd.'s CEO, Elizabeth A. Barrett, was granted 153,195 restricted stock units, vesting over three years.

UroGen Pharma's General Counsel, Jason Drew Smith, reported the vesting of restricted stock units and subsequent sales to cover tax obligations.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 7,373 ordinary shares to cover tax obligations from restricted stock unit settlements.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, reported the vesting of restricted stock units and a new RSU grant, increasing his direct beneficial ownership of ordinary shares.

UroGen Pharma Ltd.'s Chief Financial Officer, Chris Degnan, was granted 32,609 restricted stock units, vesting over three years.

UroGen Pharma Director Stuart Holden converted 2,000 restricted stock units into ordinary shares, increasing his direct ownership in the company.

UroGen Pharma Ltd. Director Cynthia M. Butitta reported a future transaction to acquire 2,000 ordinary shares through the exercise of restricted stock units under a 10b5-1 plan.

UroGen Pharma Ltd. Director James A. Robinson Jr. converted 2,000 restricted stock units into ordinary shares on November 26, 2025.

UroGen Pharma Ltd. Director Leana Wen converted 2,000 restricted stock units into ordinary shares, increasing her direct ownership.

UroGen Pharma Ltd. Director Daniel George Wildman converted 2,000 Restricted Stock Units into ordinary shares on November 26, 2025.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has filed a Form 4 indicating a planned sale of 10,000 ordinary shares in November 2025 under a pre-arranged 10b5-1 trading plan.

UroGen Pharma's CFO, Chris Degnan, sold 2,203 ordinary shares at $16.85 each to cover tax obligations following the vesting of 4,483 restricted stock units.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, exercised restricted stock units and sold a portion of the resulting shares to cover tax obligations.

UroGen Pharma's General Counsel, Jason Drew Smith, exercised restricted stock units and subsequently sold a portion of the resulting shares to cover tax obligations.

UroGen Pharma Ltd. Director Daniel George Wildman received grants of stock options and restricted stock units on August 26, 2025.

UroGen Pharma Ltd. director James A. Robinson Jr. received new stock options and restricted stock units as part of his compensation.

UroGen Pharma Ltd. Director Stuart Holden was granted 10,000 stock options and 8,000 restricted stock units, vesting quarterly over one year.

UroGen Pharma Ltd. director Cynthia M. Butitta received grants of 10,000 stock options and 8,000 restricted stock units, vesting over one year.